Amsterdam, the Netherlands and Aller?d, Denmark ? Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has signed an agreement to acquire Unisensor, an innovator in the field of optical analysis of fluids for diagnostic applications in health care, as well as other industries. The Unisensor technology and team will strengthen Philips? innovation capabilities in the field of patient sample analysis such as blood testing for applications in oncology therapy monitoring. These innovations aim to enhance patient triage and treatment at the point-of-care (i.e. near the patient), thereby helping to improve patient care at a lower cost.
Upon closing of the transaction, which is expected in the third quarter of 2014 and subject to certain closing conditions, Unisensor, headquartered in Aller?d, Denmark, will become part of Philips? Healthcare Incubator within Philips Innovation, Group & Services. Financial terms of the acquisition were not disclosed.
?Philips? Healthcare Incubator has already produced promising early-stage businesses in the area of near-patient testing and monitoring for the hospital and the home,? said Perry van Rijsingen, General Manager for Philips Healthcare Incubator. ?The acquisition of Unisensor will expand our technology platforms for miniaturized, mobile diagnostic solutions and support our ambition to become a leader in this new growth market for Philips.?
Unisensor was founded in 1997 and is a privately held company with approximately 35 employees. Unisensor?s current product line includes oCelloScope, an analytical instrument that is, amongst other applications, used within cancer cell studies on a research application basis. The company has partnerships with leading companies in animal health and water analysis, which Philips intends to continue.
For further information, please contact:
Philips Healthcare Incubator
Tel.: +31 6 10610417
E-mail: [email protected]
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Om Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) er et allsidig selskap som tilbyr et bredt spekter av helse- og velv?reprodukter. Vi ?nsker ? gi kundene v?re en bedre hverdag gjennom nyttige nyskapinger p? omr?dene Healthcare, Consumer Lifestyle and Lighting.
Philips, som har hovedkontor i Nederland, omsatte for 23,3 milliarder euro i 2013 og har om lag 113 000 medarbeidere som jobber med salg og tjenester i over hundre land. Selskapet er ledende innenfor kardiologi, pasientoverv?king og hjemmebehandling, energieffektive belysningsl?sninger og nye belysningstyper, barbering og egenpleie for menn samt munn- og tannpleie.